{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:46Z","timestamp":1793278966805,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003180","name":"Amsterdam UMC -AMC Campus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.tmaid.2022.102365","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T16:09:08Z","timestamp":1654013348000},"page":"102365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discontinuing atovaquone\/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-8130","authenticated-orcid":false,"given":"Jenny L.","family":"Schnyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Borrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hanscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tmaid.2022.102365_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkm337","article-title":"A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria","volume":"60","author":"Nakato","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102365_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0035-9203(01)90206-8","article-title":"Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model","volume":"95","author":"Berman","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102365_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0035-9203(46)90052-1","article-title":"Researches on Paludrine (M. 4888) in malaria. An experimental investigation undertaken by the LHQ medical research unit (AIF), Cairns, Australia","volume":"40","author":"Fairley","year":"1946","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102365_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0035-9203(91)90429-3","article-title":"Activity of dihydrofolate reductase inhibitors on the hepatic stages of Plasmodium yoelii yoelii in vitro","volume":"85","author":"Eriksson","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.tmaid.2022.102365_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4269\/ajtmh.1999.60.831","article-title":"Prophylactic activity of atovaquone against Plasmodium falciparum in humans","volume":"60","author":"Shapiro","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"4593","key":"10.1016\/j.tmaid.2022.102365_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bmj.1.4593.88","article-title":"Paludrine\u201d(Proguanil) in prophylaxis and treatment of malaria","volume":"1","author":"Covell","year":"1949","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.tmaid.2022.102365_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0035-9203(98)90772-6","article-title":"Challenges in the development of antimalarial drugs with causal prophylactic activity","volume":"92","author":"Chulay","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2022.102365_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tmaid.2017.12.005","article-title":"Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review","volume":"21","author":"Savelkoel","year":"2018","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102365_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/jtm.12100","article-title":"Malaria chemoprophylaxis with atovaquone-proguanil: is a shorter regimen fully protective?","volume":"21","author":"Grobusch","year":"2014","journal-title":"J Travel Med"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102365_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jtm.12088","article-title":"Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa","volume":"21","author":"Leshem","year":"2014","journal-title":"J Travel Med"},{"key":"10.1016\/j.tmaid.2022.102365_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jtm\/tay156","article-title":"Further observation of travellers taking twice-weekly atovaquone-proguanil prophylaxis in sub-Saharan Africa","volume":"26","author":"Biber","year":"2019","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102365_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cid\/ciy854","article-title":"Drug-free holidays: compliance, tolerability, and acceptability of a 3-day atovaquone\/proguanil schedule for pretravel malaria chemoprophylaxis in Australian travelers","volume":"69","author":"Lau","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.tmaid.2022.102365_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06953-4","article-title":"Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review","volume":"21","author":"Shibeshi","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.tmaid.2022.102365_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/cid\/cir770","article-title":"Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model","volume":"54","author":"Deye","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.tmaid.2022.102365_bib15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmaid.2022.102365_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jtm\/taw064","article-title":"Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone\u00ae) in long-term travellers to West Africa","volume":"23","author":"Lachish","year":"2016","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.tmaid.2022.102365_bib17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.01367-07","article-title":"Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria","volume":"52","author":"Polhemus","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tmaid.2022.102365_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0035-9203(99)90031-7","article-title":"Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya","volume":"93","author":"Shanks","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9104","key":"10.1016\/j.tmaid.2022.102365_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(97)09222-2","article-title":"Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children","volume":"351","author":"Lell","year":"1998","journal-title":"Lancet"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893922001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T21:37:47Z","timestamp":1745617067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893922001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":19,"alternative-id":["S1477893922001119"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102365","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuing atovaquone\/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2022.102365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102365"}}